相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Suppression, subversion and escape: the role of regulatory T cells in cancer progression
K. Oleinika et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Kaoru Abiko et al.
CLINICAL CANCER RESEARCH (2013)
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Omid Hamid et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
A Quantitative Deficiency in Peripheral Blood Vγ9Vδ2 Cells Is a Negative Prognostic Biomarker in Ovarian Cancer Patients
Aurelie Thedrez et al.
PLOS ONE (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves
Alexandra Sevko et al.
JOURNAL OF CANCER (2013)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells
Julien Faget et al.
CANCER RESEARCH (2012)
Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells
Curdin Conrad et al.
CANCER RESEARCH (2012)
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
Massimo Zollo et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
M. R. Shurin et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity
Jamie L. Harden et al.
IMMUNOLOGICAL INVESTIGATIONS (2012)
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
Theodore S. Johnson et al.
IMMUNOLOGICAL INVESTIGATIONS (2012)
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy
Vincent Lavoue et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells
Uciane K. Scarlett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
Suzanne Ostrand-Rosenberg et al.
SEMINARS IN CANCER BIOLOGY (2012)
Human Th17 cells in patients with cancer Friends or foe?
Tim F. Greten et al.
ONCOIMMUNOLOGY (2012)
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens
Helene Pere et al.
BLOOD (2011)
Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer
Sana Intidhar Labidi-Galy et al.
CANCER RESEARCH (2011)
PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
Natasa Obermajer et al.
CANCER RESEARCH (2011)
Th17 cells in cancer: help or hindrance?
Cailin Moira Wilke et al.
CARCINOGENESIS (2011)
Immunity and immune suppression in human ovarian cancer
Claudia C. Preston et al.
IMMUNOTHERAPY (2011)
Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma
Aifen Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer
Cailin Moira Wilke et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2011)
Immunotherapy for Ovarian Cancer: What's Next?
Lana E. Kandalaft et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy
Yuting Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Barbara Molon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
James Krempski et al.
JOURNAL OF IMMUNOLOGY (2011)
Tumour macrophages as potential targets of bisphosphonates
Thea L. Rogers et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Human Ovarian Tumor Cells Escape γδ T Cell Recognition Partly by Down Regulating Surface Expression of MICA and Limiting Cell Cycle Related Molecules
Jingwei Lu et al.
PLOS ONE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling
Ludovic Martinet et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines
Shiqian Zhang et al.
BMC CANCER (2010)
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
Joris D. Veltman et al.
BMC CANCER (2010)
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
N. Leffers et al.
BRITISH JOURNAL OF CANCER (2010)
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
J. D. Veltman et al.
BRITISH JOURNAL OF CANCER (2010)
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
Juan R. Cubillos-Ruiz et al.
CELL CYCLE (2010)
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study
Jason A. Konner et al.
CLINICAL CANCER RESEARCH (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
Chiara Napoletano et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel
P. Hoskins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2010)
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Jennifer A. Belisle et al.
MOLECULAR CANCER (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
Ilona Kryczek et al.
BLOOD (2009)
Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes
M. Stumpf et al.
BRITISH JOURNAL OF CANCER (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Intraepithelial T Cells and Tumor Proliferation
Sarah F. Adams et al.
CANCER (2009)
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
Ninke Leffers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
Uciane K. Scarlett et al.
CANCER RESEARCH (2009)
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Feng Qian et al.
CANCER RESEARCH (2009)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
Mark J. Dobrzanski et al.
CLINICAL IMMUNOLOGY (2009)
Chemokine Receptors as Targets for Cancer Therapy
Xuesong Wu et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
Peter J. Frederick et al.
GYNECOLOGIC ONCOLOGY (2009)
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
Tomoko Inaba et al.
GYNECOLOGIC ONCOLOGY (2009)
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Natalia Martin-Orozco et al.
IMMUNITY (2009)
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
Ninke Leffers et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Kellie A. Charles et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne et al.
PLOS ONE (2009)
Suppressing the suppressor: Role of immunosuppressive regulatory T cells in cancer surgery
Joel M. Baumgartner et al.
SURGERY (2009)
Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer
Michael J. Callahan et al.
CLINICAL CANCER RESEARCH (2008)
HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma
Liz Y. Han et al.
CLINICAL CANCER RESEARCH (2008)
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
Catherine S. M. Diefenbach et al.
CLINICAL CANCER RESEARCH (2008)
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
Immunogenic cancer cell death: a key-lock paradigm
Antoine Tesniere et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
Chirag A. Shah et al.
GYNECOLOGIC ONCOLOGY (2008)
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
Marketa Tomsova et al.
GYNECOLOGIC ONCOLOGY (2008)
The impact of T-cell immunity on ovarian cancer outcomes
Brad H. Nelson
IMMUNOLOGICAL REVIEWS (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A gynecologic oncology group study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
Kimberly A. Chianese-Bullock et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression
S. Peter Bak et al.
MOLECULAR IMMUNOLOGY (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
Li Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Creating immune privilege: active local suppression that benefits friends, but protects foes
Andrew L. Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
Steffen Runz et al.
GYNECOLOGIC ONCOLOGY (2007)
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma
Ilona Kryczek et al.
CANCER RESEARCH (2007)
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer
Kunle Odunsi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Srinivas Nagaraj et al.
NATURE MEDICINE (2007)
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
Pratima Sinha et al.
CANCER RESEARCH (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Self/non-self discrimination by human γδ T cells:: simple solutions for a complex issue?
Aurelie Thedrez et al.
IMMUNOLOGICAL REVIEWS (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
J. Pfisterer et al.
ANNALS OF ONCOLOGY (2006)
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)
Subhash C. Chauhan et al.
MODERN PATHOLOGY (2006)
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
Noweeda Mirza et al.
CANCER RESEARCH (2006)
Celecoxib for the prevention of colorectal adenomatous polyps
Nadir Arber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells
Rongcun Yang et al.
CANCER RESEARCH (2006)
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
I Kryczek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
S Komarova et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
V Goodell et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
B Huang et al.
CANCER RESEARCH (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
D Wolf et al.
CLINICAL CANCER RESEARCH (2005)
Regulatory T cells in ovarian cancer: Biology and therapeutic potential
B Barnett et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2005)
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
P Attia et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer
S Coleman et al.
CANCER RESEARCH (2005)
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-α-activated vascular endothelium under flow
L Yang et al.
BLOOD (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma
MR Raspollini et al.
ANNALS OF ONCOLOGY (2005)
Functional diversity and plasticity of human dendritic cell subsets
T Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas
R Drapkin et al.
CANCER RESEARCH (2005)
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125:: Immunological response and survival (Phase Ib/II)
S Reinartz et al.
CLINICAL CANCER RESEARCH (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
S Camilleri-Broet et al.
ANNALS OF ONCOLOGY (2004)
Cellular immunity in breast cancer patients completing taxane treatment
WE Carson et al.
CLINICAL CANCER RESEARCH (2004)
Immunologic principles and immunotherapeutic approaches in ovarian cancer
KL Knutson et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Soluble HLA-G molecules are increased in lymphoproliferative disorders
Y Sebti et al.
HUMAN IMMUNOLOGY (2003)
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
G Ferrandina et al.
ANNALS OF ONCOLOGY (2002)
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Tumor vaccine for ovarian carcinoma targeting sperm protein 17
M Chiriva-Internati et al.
CANCER (2002)
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
JJ Hernando et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
WP Zou et al.
NATURE MEDICINE (2001)
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
RPM Sutmuller et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Regulation of invasion of epithelial ovarian cancer by transforming growth factor-β
GC Rodriguez et al.
GYNECOLOGIC ONCOLOGY (2001)
分享论文
